Gut Bacteria May Influence Glioblastoma Growth Through Brain-Gut Axis
New review reveals how gut microbiome dysbiosis affects the most aggressive brain tumor through immune and metabolic pathways.
Summary
This comprehensive review examines how gut bacteria influence glioblastoma, the deadliest brain cancer. Researchers found that patients with glioblastoma have distinct gut microbiome patterns, with reduced beneficial bacteria and increased harmful species. The gut-brain axis allows bacterial metabolites to cross into the brain, affecting tumor growth through immune suppression and inflammation. Standard treatments like temozolomide chemotherapy work differently depending on a patient's gut bacteria composition. The findings suggest that targeting the microbiome could become a new treatment approach for this devastating cancer.
Detailed Summary
Glioblastoma (GBM) is the most aggressive brain cancer with extremely poor survival rates, but emerging research reveals an unexpected connection to gut bacteria that could revolutionize treatment approaches.
This narrative review analyzed 33 studies examining the relationship between gut microbiota and glioblastoma through the gut-brain axis. Researchers systematically reviewed evidence from clinical studies, animal models, and Mendelian randomization analyses to understand how gut bacteria influence brain tumor biology.
Key findings show that GBM patients have significantly altered gut microbiomes compared to healthy individuals. Specifically, they have reduced beneficial bacteria like Firmicutes and SCFA-producing species, while showing increased pathogenic bacteria including Enterobacteriaceae and Fusobacterium. These bacterial metabolites can cross the blood-brain barrier and directly influence the tumor microenvironment through immune modulation and inflammatory pathways.
Most importantly, the gut microbiome affects how well standard treatments work. Temozolomide chemotherapy and immune checkpoint inhibitors show different efficacy depending on a patient's bacterial composition. Certain bacterial species like Peptostreptococcaceae appear protective, while others like Adlercreutzia increase tumor risk.
These discoveries suggest that microbiome-targeted interventions—including probiotics, dietary modifications, or fecal transplants—could enhance existing treatments. However, most studies are small and observational, requiring larger clinical trials to validate therapeutic approaches. The research establishes gut bacteria as a previously unrecognized factor in brain cancer that could lead to personalized treatment strategies.
Key Findings
- GBM patients show distinct gut microbiome patterns with reduced beneficial bacteria
- Bacterial metabolites cross blood-brain barrier to influence tumor microenvironment
- Gut bacteria composition affects chemotherapy and immunotherapy effectiveness
- Specific bacterial species show protective or tumor-promoting effects
- Microbiome-targeted therapies could enhance standard GBM treatments
Methodology
This narrative review systematically analyzed 33 studies from PubMed, Scopus, and Web of Science through September 2025, focusing on microbial composition, mechanistic insights, and therapeutic interventions in glioblastoma.
Study Limitations
Most included studies had small sample sizes and were observational rather than interventional. The review did not distinguish between IDH-mutant and IDH-wildtype tumors, and mechanistic studies were primarily conducted in animal models requiring human validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.